Nuclear Diagnostic Products, Inc.
Rockaway, NJ Part of Pharmalogic Holdings Corp.
- UEI
- RQAKL78AXMT5
- CAGE
- 4H4X7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Pharmalogic Holdings Corp., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Pharmalogic Holdings Corp. · Boca Raton, FL
HVFXH4DBMXF2
-
Parent
Pharmalogic Holdings Corp. · Boca Raton, FL
HVFXH4DBMXF2
- SAM.gov registration date
- Physical address
- 101 Roundhill Dr, Rockaway, NJ 07866, USA
- Website
- ndprx.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $4,486,533 |
| FY2025 | $1,296,270 |
| FY2024 | $799,190 |
| FY2023 | $1,008,289 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $4,486,533 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Lantheus Holdings, Inc. | Bedford, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Pharmalogic Syracuse, LLC | Syracuse, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Sun Pharmaceutical Industries, Inc. | Princeton, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Midwest Positron Technology | Davenport, IA | 325412 Pharmaceutical Preparation Manufacturing |
| Mid-America Isotopes, Inc. | Ashland, MO | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Nuclear Diagnostic Products, Inc., a for-profit radiopharmaceutical manufacturer and supplier headquartered in Rockaway, New Jersey, operates as a 100% prime contractor to the Department of Veterans Affairs, delivering specialized nuclear medicine diagnostic imaging compounds — including Pylarify (Piflufolastat F 18), ILLUCCIX (Gallium 68 PSMA-11), and GA-68 NETSPOT — to VA medical facilities across the northeastern United States under full-and-open and Total Small Business set-aside delivery orders and Indefinite Delivery Contracts. The company is a subsidiary of Pharmalogic Holdings Corp.
Nuclear Diagnostic Products has maintained an established federal footprint since 2006, with 195 prime awards totaling $39.2 million in combined potential value across the past two decades. The vendor's customer base is highly concentrated within the VA system: Veterans Integrated Service Network 2 (covering New York and New Jersey) accounts for 66 awards and $20.1 million of the combined potential value, while Veterans Integrated Service Network 4 (covering Pennsylvania, New Jersey, New York, and Delaware) accounts for 21 awards and $15.5 million. Together, these two VISNs represent 92% of the vendor's combined potential value, with VISN 2 anchoring the relationship through two single-award Indefinite Delivery Contracts valued at $4.04 million and $959,170 respectively. Representative recent delivery orders include a $3.36 million Total Small Business purchase order for Pylarify injections (April 2026, ultimate completion April 2027); a $959,170 firm fixed-price delivery order for general radiopharmaceuticals to VISN 2 (February 2026); and a $374,321 delivery order modification to VISN 4 (March 2025). The vendor's top five parent vehicles — Indefinite Delivery Contracts 36C24223D0045, 36C24421D0058, VA244P0311, VA241P2090, and 36C24221D0057 — carry a combined eight to five task orders per vehicle and $2.5 million to $5.2 million in potential value per contract.
Activity accelerated from two awards in 2022 to eight in 2025, though 2026 shows four awards to date. Only three awards carry completion dates within the next twenty-four months with combined potential value of $4.5 million, indicating limited near-term recompete exposure. The vendor operates under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC code 6505 (Medical and Surgical Instruments, Equipment, and Supplies), with 72 awards classified as medical and surgical instruments and supplies and 50 classified as drugs and biologicals. Nuclear Diagnostic Products does not subcontract; 100% of its awards are prime delivery orders and IDCs issued directly by VA regional networks for daily and bulk radiopharmaceutical supply to support positron emission tomography and single-photon emission computed tomography diagnostic procedures for veteran patients.
Quick answers
Is Nuclear Diagnostic Products, Inc. registered in SAM.gov?
Yes. Nuclear Diagnostic Products, Inc.'s SAM.gov registration is active through December 22, 2026.
How much has Nuclear Diagnostic Products, Inc. received in federal contracts?
Federal contracts obligated $1,296,270 to Nuclear Diagnostic Products, Inc. in fiscal year 2025 and $7,590,282 in fiscal years 2023 through 2027.
How does Nuclear Diagnostic Products, Inc. rank among federal contractors?
Nuclear Diagnostic Products, Inc.'s parent company, Pharmalogic Holdings Corp., ranked #30 in NAICS 325412, #41 in PSC 6505 and #42 in NAICS 3254 in FY2025.
What is Nuclear Diagnostic Products, Inc.'s most recent federal award?
Nuclear Diagnostic Products, Inc.'s most recent federal contract award is Pylarify injections (36C24226P0481), from Veterans Integrated Service Network 2 (VHA), on April 2, 2026.
On GovTribe
See Nuclear Diagnostic Products, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors